Trial Profile

Phase 1 trial is a randomized, double-blinded, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profile of MP101 in adult patients with Pseudomonas aeruginosa-induced pneumonia.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Nov 2025 New trial record
27 Oct 2025 According to the Microbiotix Media Release, company announced on October 27 that it received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety (MFDS) on October 21 for MP101 and study is expected to enroll its first patient within the year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com